MovDisordV3, Main, Exploration, bibRecord, 000839

Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.

Identifieur interne : 000839 ( Main/Exploration ); précédent : 000838; suivant : 000840

Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.

Auteurs : Asako Yoritaka [Japon] ; Masashi Takanashi ; Masaaki Hirayama ; Toshiki Nakahara ; Shigeo Ohta ; Nobutaka Hattori

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2013.

RBID : pubmed:23400965

Descripteurs français

Wicri :
- geographic : Japon.

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Double-Blind Method, Female, Humans, Hydrogen (therapeutic use), Japan, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Pilot Projects, Severity of Illness Index, Statistics, Nonparametric, Water (administration & dosage).
MESH :
- chemical , administration & dosage : Water.
- chemical , therapeutic use : Antiparkinson Agents, Hydrogen, Levodopa.
- geographic : Japan.
- drug therapy : Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Statistics, Nonparametric.

Abstract

Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H₂) functions as a highly effective antioxidant in cultured cells and animal models. Drinking H₂-dissolved water (H₂-water) reduced oxidative stress and improved Parkinson's features in model animals.

DOI: 10.1002/mds.25375
PubMed: 23400965

Affiliations:

Japon
Tokyo

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.</title>
<author><name sortKey="Yoritaka, Asako" sort="Yoritaka, Asako" uniqKey="Yoritaka A" first="Asako" last="Yoritaka">Asako Yoritaka</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Takanashi, Masashi" sort="Takanashi, Masashi" uniqKey="Takanashi M" first="Masashi" last="Takanashi">Masashi Takanashi</name>
</author>
<author><name sortKey="Hirayama, Masaaki" sort="Hirayama, Masaaki" uniqKey="Hirayama M" first="Masaaki" last="Hirayama">Masaaki Hirayama</name>
</author>
<author><name sortKey="Nakahara, Toshiki" sort="Nakahara, Toshiki" uniqKey="Nakahara T" first="Toshiki" last="Nakahara">Toshiki Nakahara</name>
</author>
<author><name sortKey="Ohta, Shigeo" sort="Ohta, Shigeo" uniqKey="Ohta S" first="Shigeo" last="Ohta">Shigeo Ohta</name>
</author>
<author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="doi">10.1002/mds.25375</idno>
<idno type="RBID">pubmed:23400965</idno>
<idno type="pmid">23400965</idno>
<idno type="wicri:Area/PubMed/Corpus">000A62</idno>
<idno type="wicri:Area/PubMed/Curation">000A62</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000855</idno>
<idno type="wicri:Area/Ncbi/Merge">003A19</idno>
<idno type="wicri:Area/Ncbi/Curation">003A19</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003A19</idno>
<idno type="wicri:Area/Main/Merge">000839</idno>
<idno type="wicri:Area/Main/Curation">000839</idno>
<idno type="wicri:Area/Main/Exploration">000839</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.</title>
<author><name sortKey="Yoritaka, Asako" sort="Yoritaka, Asako" uniqKey="Yoritaka A" first="Asako" last="Yoritaka">Asako Yoritaka</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Department of Neurology, Juntendo University School of Medicine, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Takanashi, Masashi" sort="Takanashi, Masashi" uniqKey="Takanashi M" first="Masashi" last="Takanashi">Masashi Takanashi</name>
</author>
<author><name sortKey="Hirayama, Masaaki" sort="Hirayama, Masaaki" uniqKey="Hirayama M" first="Masaaki" last="Hirayama">Masaaki Hirayama</name>
</author>
<author><name sortKey="Nakahara, Toshiki" sort="Nakahara, Toshiki" uniqKey="Nakahara T" first="Toshiki" last="Nakahara">Toshiki Nakahara</name>
</author>
<author><name sortKey="Ohta, Shigeo" sort="Ohta, Shigeo" uniqKey="Ohta S" first="Shigeo" last="Ohta">Shigeo Ohta</name>
</author>
<author><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Hydrogen (therapeutic use)</term>
<term>Japan</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
<term>Water (administration & dosage)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Water</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Hydrogen</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Japan</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Statistics, Nonparametric</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Oxidative stress is involved in the progression of Parkinson's disease (PD). Recent studies have confirmed that molecular hydrogen (H₂) functions as a highly effective antioxidant in cultured cells and animal models. Drinking H₂-dissolved water (H₂-water) reduced oxidative stress and improved Parkinson's features in model animals.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Hattori, Nobutaka" sort="Hattori, Nobutaka" uniqKey="Hattori N" first="Nobutaka" last="Hattori">Nobutaka Hattori</name>
<name sortKey="Hirayama, Masaaki" sort="Hirayama, Masaaki" uniqKey="Hirayama M" first="Masaaki" last="Hirayama">Masaaki Hirayama</name>
<name sortKey="Nakahara, Toshiki" sort="Nakahara, Toshiki" uniqKey="Nakahara T" first="Toshiki" last="Nakahara">Toshiki Nakahara</name>
<name sortKey="Ohta, Shigeo" sort="Ohta, Shigeo" uniqKey="Ohta S" first="Shigeo" last="Ohta">Shigeo Ohta</name>
<name sortKey="Takanashi, Masashi" sort="Takanashi, Masashi" uniqKey="Takanashi M" first="Masashi" last="Takanashi">Masashi Takanashi</name>
</noCountry>
<country name="Japon"><noRegion><name sortKey="Yoritaka, Asako" sort="Yoritaka, Asako" uniqKey="Yoritaka A" first="Asako" last="Yoritaka">Asako Yoritaka</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000839 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000839 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23400965
   |texte=   Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23400965" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.

Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.